Public Sector Pension Investment Board Takes Position in Progyny, Inc. (NASDAQ:PGNY)

Public Sector Pension Investment Board bought a new stake in Progyny, Inc. (NASDAQ:PGNY - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 166,600 shares of the company's stock, valued at approximately $2,792,000. Public Sector Pension Investment Board owned approximately 0.18% of Progyny as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Pacer Advisors Inc. increased its position in Progyny by 12,579.4% during the third quarter. Pacer Advisors Inc. now owns 2,492,642 shares of the company's stock worth $41,777,000 after buying an additional 2,472,983 shares during the last quarter. International Assets Investment Management LLC increased its position in Progyny by 1,576.0% during the third quarter. International Assets Investment Management LLC now owns 2,565,118 shares of the company's stock worth $42,991,000 after buying an additional 2,412,068 shares during the last quarter. Farallon Capital Management LLC increased its position in Progyny by 120.8% during the second quarter. Farallon Capital Management LLC now owns 1,308,500 shares of the company's stock worth $37,436,000 after buying an additional 715,900 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Progyny by 24.8% during the second quarter. Dimensional Fund Advisors LP now owns 1,281,928 shares of the company's stock worth $36,676,000 after buying an additional 254,725 shares during the last quarter. Finally, Millennium Management LLC grew its position in shares of Progyny by 77.8% in the second quarter. Millennium Management LLC now owns 535,962 shares of the company's stock valued at $15,334,000 after purchasing an additional 234,590 shares during the last quarter. Hedge funds and other institutional investors own 94.93% of the company's stock.

Progyny Stock Down 0.5 %

PGNY traded down $0.07 during midday trading on Wednesday, reaching $14.78. 420,238 shares of the company's stock were exchanged, compared to its average volume of 1,397,608. The firm has a market capitalization of $1.26 billion, a price-to-earnings ratio of 25.60, a price-to-earnings-growth ratio of 1.80 and a beta of 1.35. Progyny, Inc. has a one year low of $13.39 and a one year high of $42.08. The business has a 50-day simple moving average of $15.74 and a two-hundred day simple moving average of $21.98.

Progyny (NASDAQ:PGNY - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $0.11 EPS for the quarter, missing analysts' consensus estimates of $0.37 by ($0.26). The business had revenue of $286.63 million for the quarter, compared to the consensus estimate of $296.85 million. Progyny had a return on equity of 11.36% and a net margin of 5.03%. The firm's revenue for the quarter was up 2.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.16 EPS. As a group, research analysts anticipate that Progyny, Inc. will post 0.58 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on PGNY. Leerink Partnrs downgraded Progyny from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 7th. Canaccord Genuity Group lowered their price target on Progyny from $18.00 to $17.00 and set a "hold" rating on the stock in a research report on Wednesday, November 13th. JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $17.00 price target (down from $22.00) on shares of Progyny in a research report on Monday. Canaccord Genuity Group downgraded Progyny from a "buy" rating to a "hold" rating and lowered their price target for the company from $37.00 to $24.00 in a research report on Wednesday, August 7th. Finally, JMP Securities downgraded Progyny from an "outperform" rating to a "market perform" rating in a research report on Thursday, September 19th. Nine equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $25.00.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.